Get started
Mankind Pharma Ltd.Mankind Pharma Ltd.Mankind Pharma Ltd.

Mankind Pharma Ltd.

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsIdeasDiscussionsTechnicalsForecastSeasonalsOptionsBondsETFs

MANKIND chart


Full chart

MANKIND upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.02 T‬ INR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
54.35
Basic EPS (TTM)
46.60 INR
Net income (FY)
‪19.91 B‬ INR
Revenue (FY)
‪122.07 B‬ INR
Shares float
‪112.67 M‬
Beta (1Y)
0.84

Employees


Employees (FY)
‪21.32 K‬
Change (1Y)
‪+1.78 K‬ +9.14%
Revenue / Employee (1Y)
‪5.72 M‬ INR
Net income / Employee (1Y)
‪931.50 K‬ INR

About Mankind Pharma Ltd.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Sheetal Arora
Website
mankindpharma.com
Headquarters
New Delhi
Founded
1986
ISIN
INE634S01028
FIGI
BBG01G9WXGC8
Mankind Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations across acute and chronic therapeutic areas. It offers products under the brands of Nurokind, Telmikind, Manforce, Unwanted, Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Prega News, Dydroboon, Cefakind, Monticope, and Caldikind. The company was founded by Ramesh Chand Juneja in 1986 and is headquartered in New Delhi, India.

Check out other big names from the same industry as MANKIND.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

MANKIND news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

MANKIND highest yielding bonds


797MPL27
Mankind Pharma Limited 7.97% 16-NOV-2027
Yield to maturity
—
Maturity date
Nov 16, 2027
799MPL26A
Mankind Pharma Limited 7.99% 16-OCT-2026
Yield to maturity
—
Maturity date
Oct 16, 2026
799MPL26
Mankind Pharma Limited 7.99% 16-APR-2026
Yield to maturity
—
Maturity date
Apr 16, 2026

See all MANKIND bonds 

Frequently Asked Questions


The current price of MANKIND is 2,462.00 INR — it has increased by 0.53% in the past 24 hours. Watch Mankind Pharma Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange Mankind Pharma Ltd. stocks are traded under the ticker MANKIND.
MANKIND stock has fallen by −6.65% compared to the previous week, the month change is a 0.33% rise, over the last year Mankind Pharma Ltd. has showed a −7.39% decrease.
We've gathered analysts' opinions on Mankind Pharma Ltd. future price: according to them, MANKIND price has a max estimate of 3,160.00 INR and a min estimate of 2,150.00 INR. Watch MANKIND chart and read a more detailed Mankind Pharma Ltd. stock forecast: see what analysts think of Mankind Pharma Ltd. and suggest that you do with its stocks.
MANKIND reached its all-time high on Dec 23, 2024 with the price of 3,054.80 INR, and its all-time low was 1,242.00 INR and was reached on May 22, 2023. View more price dynamics on MANKIND chart.
See other stocks reaching their highest and lowest prices.
MANKIND stock is 1.88% volatile and has beta coefficient of 0.84. Track Mankind Pharma Ltd. stock price on the chart and check out the list of the most volatile stocks — is Mankind Pharma Ltd. there?
Today Mankind Pharma Ltd. has the market capitalization of ‪1.02 T‬, it has decreased by −1.08% over the last week.
Yes, you can track Mankind Pharma Ltd. financials in yearly and quarterly reports right on TradingView.
Mankind Pharma Ltd. is going to release the next earnings report on Nov 4, 2025. Keep track of upcoming events with our Earnings Calendar.
MANKIND earnings for the last quarter are 10.70 INR per share, whereas the estimation was 10.92 INR resulting in a −1.98% surprise. The estimated earnings for the next quarter are 13.70 INR per share. See more details about Mankind Pharma Ltd. earnings.
Mankind Pharma Ltd. revenue for the last quarter amounts to ‪35.70 B‬ INR, despite the estimated figure of ‪36.04 B‬ INR. In the next quarter, revenue is expected to reach ‪38.06 B‬ INR.
MANKIND net income for the last quarter is ‪4.38 B‬ INR, while the quarter before that showed ‪4.21 B‬ INR of net income which accounts for 4.17% change. Track more Mankind Pharma Ltd. financial stats to get the full picture.
Mankind Pharma Ltd. dividend yield was 0.00% in 2024, and payout ratio reached 0.00%. The year before the numbers were 0.00% and 0.00% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 30, 2025, the company has ‪21.32 K‬ employees. See our rating of the largest employees — is Mankind Pharma Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Mankind Pharma Ltd. EBITDA is ‪32.10 B‬ INR, and current EBITDA margin is 25.41%. See more stats in Mankind Pharma Ltd. financial statements.
Like other stocks, MANKIND shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Mankind Pharma Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Mankind Pharma Ltd. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Mankind Pharma Ltd. stock shows the buy signal. See more of Mankind Pharma Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.